Screening for Subsequent Pancreatic Cancer in Childhood Cancer Survivors is Needed. A Case Report

Lorna Zadravec Zaletel1, Miha Cavlek and Mojca Gjidera

Department of Radiation Oncology, Institute of Oncology, Zaloška 2, 1000, Ljubljana, Slovenia

E-mail: lzaletel@onko-i.si

Received date: November 14, 2017; Accepted date: November 20, 2017; Published date: November 27, 2017

Keywords: Subsequent pancreas cancer; Childhood cancer survivor; Late effects; Subsequent primary neoplasm; Screening

Abstract

Introduction: The survival of children with cancer has improved considerably over the last decades which have led to a growing number of long term survivors. One of the most serious adverse outcomes in this population is subsequent primary neoplasms with the risk as high as six-fold over expected. The relative risk for subsequent pancreatic cancer in childhood cancer survivors is high, especially after subdiafragmatic radiotherapy and/or chemotherapy with alkylating agents. The survival of patient with advanced pancreatic cancer is very low, and early diagnosis is of vital importance.

Case report: We present a female patient, treated for Ewing sarcoma of thoracic wall with multimodal treatment at the age of 5. She received chemotherapy containing a high dose of Cyclophosphamide and postoperative radiotherapy to the left hemithorax with the dose of 15 Gy followed by local boost to the tumour bed. She had regular follow-ups at the Late-effect clinic at the Institute of Oncology in Ljubljana. Well differentiated papillary cancer of thyroid with nodal metastases was diagnosed during a regular neck ultrasound 26 years after the completion of cancer treatment. Two years later, at the age of 33, she presented with abdominal distension, inappetence and diffuse liver metastases with ascites were found by abdominal ultrasound. Tumour marker CA 19-9 was high, but hepatic metastases showed poorly differentiated adenocarcinoma. The disease progressed very fast and she died a month after the appearance of the first symptom. The autopsy revealed poorly differentiated adenocarcinoma of the pancreatic head and body with multiple metastases in abdominal organs and lungs.

Conclusion: It would be reasonable to introduce the same guidelines for screening of subsequent pancreatic cancer in childhood cancer survivors at high risk for subsequent pancreas cancer as proposed for patients with increased risk for familial pancreatic cancer.

Introduction

The survival of children with cancer has improved considerably over the last decades which have led to a growing number of long term survivors. It is estimated that there are between 300,000 and 500,000 survivors of childhood cancer in Europe [1]. A significant proportion of childhood cancer survivors (CCS) suffer adverse health outcomes including premature mortality, compared with general population [2]. One of the most serious adverse outcomes is subsequent primary neoplasms (SPNs), with the risk as high as six-fold over expected [3-6].

The risk of developing a SPN of gastrointestinal tract is high. Tukenova et al observed 9.7-fold higher risk of SPNs in CCS in relation to general population in France and the United Kingdom. The relative risk of subsequent pancreatic cancer (SPC) in this cohort was 9.9 [7]. High risk of pancreatic cancer (odds ratio of 19) was observed in patients treated for Hodgkin’s lymphoma with subdiafragmatic radiotherapy (RT) and > 6 cycles of chemotherapy (ChT) with alkylating agents (AA) [8]. A lower relative risk (3.6) of SPC was reported in adult patients with testicular cancer [9]. The survival of patients with advanced pancreatic cancer is very low, and early diagnosis is of vital importance [10]. To our knowledge no guidelines exist for the screening of pancreatic cancer in CCS who are at high risk for SPC.

Hereinafter, we describe the history of a female patient, treated for Ewing sarcoma of thoracic wall with multimodal treatment at the age of 5, who died of SPC with fulminant course 28 years after the treatment.

Case Report

Our female patient was treated in 1987, at the age of five for Ewing sarcoma of the posterior part of the left fifth rib with infiltration of adjacent soft tissue. Wide resection of the tumour was performed after 3 cycles of preoperative ChT according to T6 protocol. A total necrosis was found in microscopic examination. The patient received postoperative RT with the dose of 15 Gy in 1.5 Gy fractions to the left hemithorax with cobalt gamma rays through antero-posterior and postero-anterior field, followed by boost with electrons (10 MeV) to the tumour bed at the upper half of left posterior thoracic wall with 14
Gy in 7 fractions. Postoperative ChT according to T2 protocol was administered for one and a half year. Cumulative doses of cytostatics were: 17500 mg/m$^2$ of Cyclophosphamide, 370 mg/m$^2$ of Adriablastine, 11000 mg/m$^2$ of Dactinomycin, 48 mg/m$^2$ of Vincristine, 75 mg/m$^2$ of Bleomycine and 85 mg/m$^2$ of MTX.

Following that, she had regular follow-ups, at first at the Paediatric clinic, and from the age of 16 at the Late-effect clinic at the Institute of Oncology in Ljubljana [11]. There, regular screening for secondary breast cancer and regular tests of cardiac and thyroid function were performed. In 2013, 2 years after the end of cancer treatment, at the age of 31, at a routine ultrasound of the neck, nodule 6 mm in diameter was found in the left thyroid lobe. A cytology test pointed to a papillary cancer. A total thyroidectomy and modified dissection of neck lymph nodes was done. Histology revealed well differentiated papillary cancer in the left thyroid lobe with lymph node metastases in the first three levels of left neck. After the surgery the patient underwent ablation of the thyroid tissue with radioactive iodine 131-I (96 mCi).

A year later, fibroadenoma at the border of outer quadrants of the right breast was diagnosed by biopsy of the lesion seen on diagnostic MRI. In May 2015, at a regular control at the clinic for long-term follow-up she felt well, with no complaints, her clinical test was ok, blood test was scheduled in 3 months. However, one and a half months later she came back with medical reports from a regional hospital where laparoscopic gallbladder stone surgery had been planned but was not performed due to abdominal distension. Abdominal ultrasound found finely granulated liver and ascites. Abdominal CT revealed numerous liver metastases, moderate hydrenephrosis of the left kidney, other abdominal organs, including pancreas, were morphologically normal (Figures 1 and 2). She complained because of abdominal distension, inappetence.

A physical examination showed that she was malnourished, WHO performance status was 2, abdominal distension was seen, caused by extensive ascites. Fine needle aspiration of hepatic lesion was performed and cytological test showed poorly differentiated adenocarcinoma. In the cytology test of ascites, peritoneal carcinosis was found. Blood tests showed elevated levels of hepatic enzymes, direct bilirubin and abnormal tumour markers CEA (155, normal<4.7) and CA 19-9 (2118, normal<30). She was hospitalised at the Institute of Oncology and abdominal helical CT was performed, showing huge ascites, many hepatic metastases, largest 6.5 cm in diameter, marginally enlarged left paraaortic lymph nodes, enlargement of both ovaries. Pancreas looked normal, even pancreatic duct did not appear dilated on CT. Multidisciplinary team proposed symptomatic treatment because of poor performance status. Namely, her physical condition was worsening very quickly from day to day and she died 10 days after admission to the hospital. Autopsy was performed and revealed poorly differentiated adenocarcinoma of the pancreatic head and body, invading into peripancreatic soft tissue and the wall of stomach. Multiple metastases with massive lymphovascular invasion of lung, spleen, gallbladder, both suprarenal glands, mesentery, small bowel wall, uterus, adnexes and abdominal lymph nodes were found.
Discussion

Our patient experienced a fulminant course of SPC and died a month after the appearance of the first, nonspecific, symptom of metastatic pancreas cancer. In childhood she underwent RT to the left hemithorax with the dose of 15 Gy and most likely at least upper part of the pancreas was in RT field. Beside that she received a high cumulative dose of AA Cyclophosphamide. According to the literature, RT and ChT with AA are important cause of SPC. In the report of Dores et al, SPC risk after treatment of Hodgkin lymphoma increased with increasing radiation dose to the pancreatic tumour location and increasing number of AA-containing cycles of ChT, especially high risk was observed in patients receiving ≥3900 mg/m² of cyclophosphamide (8). The odds ratio for patients treated with both subdiaphragmatic radiation (≥10 Gy) and ≥26 AA-containing ChT cycles compared with patients with neither treatment was as high as 17.9. Hauptmann et al in the case-control study in testicular cancer patients reported that odds ratio of SPC increased linearly by 0.12 per Gy to the pancreas [12].

In our patient, SPC was neither detected by abdominal ultrasound nor fine-needle aspiration to evaluate cysts, as early as 17 years after the end of treatment [7,8].

Our patient suffered from subsequent well differentiated papillary cancer as well, most likely caused by RT. Small tumour was detected on routine ultrasound, but nodal metastases were already present. Thyroid cancers are beside breast cancers the most common SPN in CCS and are mostly well differentiated cancer with excellent prognosis [19].

Currently there is no consensus on the optimal surveillance strategy for thyroid cancer after radiotherapy in CCS. The use of ultrasound for early diagnosis of radiation-induced thyroid cancer may be suitable, nevertheless, routine ultrasound screening in irradiated CCS can actually not be recommended [20].

Acknowledgement

We thank for financial support to Slovenian Research Agency.

References


